Site search
2816 results for '' found
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
/research/clinical-trials/find-clinical-trials/a-phase-3-multicentre-randomised-double-blind-placebo-controlled-study-of-oral-ozanimod-as-induction-therapy-for-moderately-to-severely-active-crohns-disease-celgene-3202-nct03440385
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
/research/clinical-trials/find-clinical-trials/a-phase-3-multicenter-open-label-extension-study-of-oral-ozanimod-for-moderately-to-severely-active-crohns-disease-nct03467958
INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372
INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372
/research/clinical-trials/find-clinical-trials/induction-study-1-a-phase-3-multicenter-randomized-double-blindplacebo-controlled-study-of-oral-ozanimod-as-induction-therapy-for-moderately-to-severely-active-crohns-disease-nct03440372
Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)
Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)
/research/clinical-trials/find-clinical-trials/red-blood-cell-transfusion-in-ecmo-a-feasibility-trial-nct05814094
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-sev
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-sev
/research/clinical-trials/find-clinical-trials/a-phase-3-randomized-24-week-placebo-controlled-double-blind-study-to-assess-the-efficacy-safety-and-tolerability-of-rocatinlimab-amg-451-monotherapy-in-adult-subjects-with-moderate-to-sev
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Derma
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Derma
/research/clinical-trials/find-clinical-trials/a-phase-3-multicenter-double-blind-maintenance-study-to-assess-long-term-safety-tolerability-and-efficacy-of-rocatinlimab-in-adult-and-adolescent-subjects-with-moderate-to-severe-atopic-derma
Reduction Of Chronic Post-surgical Pain with Ketamine - ROCKet Trial (ACTRN12617001619336)
Reduction Of Chronic Post-surgical Pain with Ketamine - ROCKet Trial (ACTRN12617001619336)
/research/clinical-trials/find-clinical-trials/reduction-of-chronic-post-surgical-pain-with-ketamine-rocket-trial-actrn12617001619336
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cance
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cance
/research/clinical-trials/find-clinical-trials/a-first-in-human-study-of-mutant-selective-pi3ka-inhibitor-rly-2608-as-a-single-agent-in-advanced-solid-tumor-patients-and-in-combination-with-fulvestrant-in-patients-with-advanced-breast-cance
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (NCT04905693)
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (NCT04905693)
/research/clinical-trials/find-clinical-trials/an-open-label-extension-study-of-inhaled-treprostinil-in-subjects-with-idiopathic-pulmonary-fibrosis-nct04905693
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
/research/clinical-trials/find-clinical-trials/a-phase-2b-multinational-randomized-double-blind-study-to-investigate-the-efficacy-and-safety-of-redasemtide-s-005151-compared-with-placebo-in-adult-participants-with-acute-ischemic-stroke-w